Today, iCoat Medical welcomes Jacob Westman as its Head of Chemistry, Manufacturing and Controls on a consultancy basis.
iCoat Medical has a growing pipeline of indications as well as an ambitious clinical program outlined for the coming years. The company aim to not only expand its clinical program for TUM012 but also advance its second product family TUM020 towards clinical stage. As part of this future development, iCoat Medical will need to increase its CMC-operations in order to be prepared for a future commercial launch of its products.
“Jacob brings extensive experience from the fields of chemistry, toxicological studies, GMP-product development, and patent portfolio management as well as international line management experience. I am very happy to welcome him as a member of iCoat Medical’s management team and look forward to working with him in the future” says iCoat Medical’s CEO Peder Waern.
Jacob is currently also working part-time at Curovir where he is the Head of preclinical research and development with an end-to-end responsibility for all preclinical research and development, patent portfolio management and patent strategy and all CMC activities. Previously, he has held senior positions at Apodemus, Betagenon, Karolinska Development, Pharmacia & Upjohn and Kabi Pharmacia.
Jacob is an associate professor at Stockholm University and holds a Ph.D. in organic chemistry.
For more information, please contact:
Peder Waern, CEO – iCoat Medical AB
E-mail: peder.waern@icoatmedical.com